US equities |
MU $928.76 ▲+0.00% SNDK $1,304.84 ▲+0.00% SKHY $145.36 ▲+0.00% TSLA $407.46 ▲+0.00% NVDA $217.94 ▲+0.00% GOOGL $320.58 ▲+0.00% STX $667.85 ▲+0.00% GEV $895.08 ▲+0.00%
FinancialContent

ResMed Inc. Common Stock (NY:RMD)

250.80 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
ResMed (RMD) Q3 earnings report preview: what to look for
Medical device company ResMed (NYSE:RMD) will be reporting results this Thursday after market hours. Here’s what you need to know. ResMed met analysts’ reven... 
Via StockStory
Topics Artificial Intelligence
News headline image
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
Latest addition to Resmed’s growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choice 
From Resmed, Inc.
Via GlobeNewswire
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals ↗
Via Chartmill
News headline image
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings?
ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell short of... 
Via StockStory
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts ↗
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume. ↗
Via Chartmill
ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% ↗
Via Chartmill
News headline image
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand ↗
ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing... 
Via MarketBeat
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
News headline image
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers. Patient monit... 
Via StockStory
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
From Pomerantz LLP
Via GlobeNewswire
News headline image
2 Profitable Stocks Worth Investigating and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
From Resmed, Inc.
Via GlobeNewswire
News headline image
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
From Pomerantz LLP
Via GlobeNewswire
News headline image
23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
From Resmed, Inc.
Via GlobeNewswire
News headline image
ResMed (RMD) Q4 2026 Earnings Call Transcript ↗
Farrell discusses strategic divestitures, capital returns, and AI digital health expansion. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management ... 
Via StockStory
Topics Earnings Economy
Which S&P500 stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
ResMed Q4 Earnings Call Highlights ↗
ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share... 
Via MarketBeat
Topics Earnings Economy
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
Top S&P500 movers in Friday's session ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Which S&P500 stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ... 
Via StockStory
Topics Economy
News headline image
ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >